Data gathered: September 17
AI Stock Analysis - Solid Biosciences (SLDB)
Analysis generated August 28, 2025. Powered by Chat GPT.
Solid Biosciences is a biopharmaceutical company dedicated to advancing transformative treatments for patients with Duchenne muscular dystrophy (DMD). The company focuses on addressing the unmet needs of the DMD patient community by developing innovative therapies that have the potential to improve patient outcomes. Through a rigorous R&D process, Solid Biosciences is positioning itself as a key player in the biotech space.
Stock Alerts - Solid Biosciences (SLDB)
 |
Solid Biosciences | September 10 Price is up by 6.4% in the last 24h. |
|
Solid Biosciences | September 8 Price is down by -6.4% in the last 24h. |
|
Solid Biosciences | September 3 Price is up by 6.2% in the last 24h. |
|
Solid Biosciences | August 19 AI Score is up by 23% in the last couple of days. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Solid Biosciences
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 9 | Sign up | Sign up | Sign up |
| Sentiment | 88 | Sign up | Sign up | Sign up |
| Webpage traffic | 7,000 | Sign up | Sign up | Sign up |
| Employee Rating | 78 | Sign up | Sign up | Sign up |
| Google Trends | 8 | Sign up | Sign up | Sign up |
| Patents | 7 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 8 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 6,103 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,534 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 64 | Sign up | Sign up | Sign up |
| Linkedin Employees | 137 | Sign up | Sign up | Sign up |
About Solid Biosciences
Solid Biosciences Inc., a life science company, engages in developing therapies for neuromuscular and cardiac diseases in the United States.
| Price | $5.41 |
| Target Price | Sign up |
| Volume | 715,020 |
| Market Cap | $428M |
| Year Range | $2.52 - $7.07 |
| Dividend Yield | 0% |
| PE Ratio | 0.16 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Solid Biosciences (NASDAQ:SLDB) Downgraded by Wall Street Zen to SellSeptember 14 - ETF Daily News |
 |
Solid Biosciences Inc. $SLDB Shares Sold by Trexquant Investment LPSeptember 8 - ETF Daily News |
|
American Century Companies Inc. Acquires 4,978 Shares of Solid Biosciences Inc. $SLDBSeptember 8 - ETF Daily News |
|
Solid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Recommendation of “Buy” by BrokeragesSeptember 3 - ETF Daily News |
 |
Solid Biosciences Inc. (SLDB) Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 2 - SeekingAlpha |
Solid Biosciences to Participate at Upcoming Investor ConferencesAugust 28 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '25 | 0 | 0 | 0 | -39M | -42M | -0.420 |
| Q1 '25 | 0 | 410,000 | -410,000 | -39M | -40M | -0.590 |
| Q4 '24 | 3.1M | 490,000 | -490,000 | -43M | -42M | -1.000 |
| Q3 '24 | 0 | 410,000 | -410,000 | -33M | -32M | -0.790 |
| Q2 '24 | 0 | 1.2M | -1.2M | -25M | -24M | -0.610 |
Insider Transactions View All
| Kahn Clare filed to buy 2,960 shares at $5.3. March 13 '25 |
| BCIP Life Sciences Associates, LP filed to buy 5,034,582 shares at $4. February 21 '25 |
| BCIP Life Sciences Associates, LP filed to buy 6,444,170 shares at $4. February 21 '25 |
| EDELMAN JOSEPH filed to buy 11,833,539 shares at $4. February 21 '25 |
| RA Capital Healthcare Fund LP filed to buy 3,722,085 shares at $4. February 21 '25 |
Similar companies
Read more about Solid Biosciences (SLDB) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Solid Biosciences?
The Market Cap of Solid Biosciences is $428M.
What is Solid Biosciences' PE Ratio?
As of today, Solid Biosciences' PE (Price to Earnings) ratio is 0.16.
What is the current stock price of Solid Biosciences?
Currently, the price of one share of Solid Biosciences stock is $5.41.
How can I analyze the SLDB stock price chart for investment decisions?
The SLDB stock price chart above provides a comprehensive visual representation of Solid Biosciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Solid Biosciences shares. Our platform offers an up-to-date SLDB stock price chart, along with technical data analysis and alternative data insights.
Does SLDB offer dividends to its shareholders?
As of our latest update, Solid Biosciences (SLDB) does not offer dividends to its shareholders. Investors interested in Solid Biosciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Solid Biosciences?
Some of the similar stocks of Solid Biosciences are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.